Endo International (ENDPQ) 10-Q2019 Q2 Quarterly report

Filed: 5 Aug 19, 5:00pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: AstraZeneca, attract, Blaise, budesonide, Code, Coleman, Coughlin, disaggregated, embedded, entecavir, entirety, ethyl, excise, fluoxetine, flutamide, fumarate, Handa, hydroxyurea, inactive, inline, Irish, labetalol, leadership, Maletta, Matthew, Ministry, Missouri, multinational, NEO, Nevakar, Oklahoma, outlined, preliminarily, progressing, qualitative, quantitative, Quebec, reasserted, recipient, Regent, regime, retroactive, saving, Seroquel, Terrance, text, thereunder, thirty, transformational, turnaround, unearned, upheld, Vice, XR

Removed: achieve, advisory, agent, allegedly, Analgesic, Anesthetic, careful, ceased, chain, complexity, consultation, coordinate, core, covering, decided, decline, delayed, FFDCA, harm, historic, implemented, incentive, intention, labeling, large, marketable, marketed, meeting, modification, monitor, NDA, negatively, orderly, outweigh, point, practice, publicly, refusal, restated, safety, satisfy, Seiyaku, shift, substance, support, Teikoku, traded, unapproved, unrealized, voted, withdraw, withdrawal, work, write, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ENDPQ transcripts

ENDPQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul V. Campanelli, as President and Chief Executive Officer of Endo International plc (the Company), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2019 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




		/S/ PAUL V. CAMPANELLI
Name:		Paul V. Campanelli
Title:		President and Chief Executive Officer (Principal Executive Officer)

Date: August 5, 2019

A signed original of this written statement required by Section 906 has been provided to, and will be retained by, Endo International plc and furnished to the Securities and Exchange Commission or its staff upon request.